Condition

Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified clinical trials and research

• 5Clinical trials
• 1Country

Newest Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified clinical trials

All recruiting trials (5)

• Epcoritamab plus R-GemOx before autologous stem cell transplant for relapsed or refractory DLBCL

  This phase II trial tests whether adding epcoritamab to rituximab with gemcitabine and oxaliplatin (R-GemOx) can help adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) achieve remission and proceed to autologous stem cell transplant.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07365306

• Epcoritamab with platinum chemotherapy and autologous stem cell transplant for relapsed or refractory large B-cell lymphoma

  This trial tests whether adding epcoritamab to standard platinum-based salvage chemotherapy followed by an autologous stem cell transplant helps adults with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06905509

• Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma

  This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT06834373

• ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

  This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

  Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

• Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma

  This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.

  Recruiting at 3 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Minneapolis, Minnesota and 2 other locations · NCT06536049

Related topics

Quick answers

How many Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified clinical trials are recruiting right now?

5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →